24/7 Market News Snapshot 09 October, 2025 – Bluejay Diagnostics, Inc. Common Stock (NASDAQ:BJDX)
DENVER, Colo., 09 October, 2025 (www.247marketnews.com) – (NASDAQ:BJDX) are discussed in this article.
Bluejay Diagnostics, Inc. (BJDX) has recently made headlines with a significant surge in its stock price, opening at $3.79 and currently trading at $3.48, which marks an impressive 86.10% increase from the previous day’s close of $1.87. This surge has generated considerable investor interest, fueled by robust trading activity that recorded 101.65 million shares exchanged. Market enthusiasm appears to be driven by strategic advancements related to the company’s pioneering diagnostic solutions, presenting an appealing opportunity for investors keen on capitalizing on this momentum.
In addition to this market performance, Bluejay Diagnostics has announced the completion of definitive agreements for a private placement offering, a crucial step in bolstering its financial foundation. The company plans to issue 2,250,000 shares of common stock along with Series F warrants that allow for the purchase of an additional 4,500,000 shares at a price of $2.00 per share. The anticipated gross proceeds from this offering are approximately $4.5 million, earmarked for critical clinical studies necessary to obtain FDA approval for its innovative diagnostic technologies.
The Series F warrants will feature an exercise price of $1.75 per share and will be immediately exercisable upon issuance, remaining valid for a period of 5.5 years, thus providing shareholders with a valuable investment opportunity. Bluejay Diagnostics is dedicated to enhancing patient outcomes through its Symphony System, a state-of-the-art near-patient testing platform for sepsis triage and monitoring. The company’s flagship product, the IL-6 Test, promises to deliver accurate results within approximately 20 minutes, empowering medical professionals to make prompt and informed treatment decisions. This latest financial maneuver positions Bluejay on a trajectory for continued growth and innovation in the healthcare diagnostics sector.